Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
FranceIPO:
22 October 2014Website:
http://www.dbv-technologies.comNext earnings report:
31 July 2024Last dividends:
N/ANext dividends:
N/APrice
pre-market | 43 min agoDividend
Analysts recommendations
Institutional Ownership
DBVT Latest News
Châtillon, France, June 5, 2024 DBV Technologies to Participate in the Goldman Sachs 45 th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the 45th Annual Goldman Sachs Global Healthcare Conference on Monday, June 10th, at 8:00 am EDT, as well as in one-on-one investor meetings. A live webcast of the presentation can be accessed here, and will also be available on the Events section of Company's Investors website: https://dbv-technologies.com/investor-overview/events/ A replay will also be available on DBV Technologies' website for 90 days after the event.
Châtillon, France, May 31, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, previously announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value €0.10 (ten cents) per share, from the current ADS Ratio of one (1) ADS to one-half (1/2) of one (1) ordinary share to a new ADS Ratio of one (1) ADS to one (1) ordinary share (the “ADS Ratio Change”) to be effective on or about June 3rd, 2024. The Company now anticipates that the ADS Ratio Change will be effective on or about June 7th, 2024 (the “Effective Date”).
Châtillon, France, May 30, 2024 DBV Technologies to Participate in Upcoming EAACI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced its upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress May 31 – June 3 in Valencia, Spain. A flash talk presentation by Nicolette Arends, M.D.
DBV Technologies, a biopharmaceutical company specializing in food allergies and other immunologic conditions, has announced plans to change the ratio of its American Depositary Shares to ordinary shares. The current ratio of 1 ADS to 1/2 ordinary share will be adjusted to 1 ADS to 1 ordinary share. The change is expected to take effect on June 3, 2024.
DBV Technologies has announced the results of its 2024 Combined General Meeting in Châtillon, France on May 16th. Shareholders approved all proposed resolutions at the meeting, which was chaired by Michel de Rosen, the Chairman of the Company.
Montrouge, France, March 4, 2024 DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced the Company will host a conference call and live audio webcast on Thursday, March 7th, at 5:00 p.m. ET to review full year 2023 financial results and provide a business update.
DBV Technologies S.A. (DBVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
Montrouge, France, November 2, 2023 DBV Technologies to Present New Data at ACAAI 2023 New data to include late-breaking abstract detailing interim 12-month results from the ongoing Phase 3 open-label extension to the EPITOPE trial (EPOPEX) of Viaskin™ Peanut in peanut-allergic toddlers. DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new data on the use of Viaskin™ Peanut (DBV712) 250 μg in peanut-allergic toddlers will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, which is being held Thursday, November 9 – Monday, November 13, 2023, in Anaheim, CA.
DBV Technologies S.A. (NASDAQ:DBVT ) Q3 2023 Earnings Conference Call October 31, 2023 5:00 PM ET Company Participants Katie Matthews - Head of Investor Relations Daniel Tassé - Chief Executive Officer Pharis Mohideen - Chief Medical Officer Conference Call Participants Rajan Sharma - Goldman Sachs Operator Welcome to the DBV's Third Quarter Financial Results and Business and Regulatory Update Conference Call.
Montrouge, France, October 27, 2023 DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, October 31st, at 5:00 p.m. ET to review third quarter 2023 financial results and provide a business update.
What type of business is DBV Technologies SA?
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
What sector is DBV Technologies SA in?
DBV Technologies SA is in the Healthcare sector
What industry is DBV Technologies SA in?
DBV Technologies SA is in the Biotechnology industry
What country is DBV Technologies SA from?
DBV Technologies SA is headquartered in France
When did DBV Technologies SA go public?
DBV Technologies SA initial public offering (IPO) was on 22 October 2014
What is DBV Technologies SA website?
https://www.dbv-technologies.com
Is DBV Technologies SA in the S&P 500?
No, DBV Technologies SA is not included in the S&P 500 index
Is DBV Technologies SA in the NASDAQ 100?
No, DBV Technologies SA is not included in the NASDAQ 100 index
Is DBV Technologies SA in the Dow Jones?
No, DBV Technologies SA is not included in the Dow Jones index
When does DBV Technologies SA report earnings?
The next expected earnings date for DBV Technologies SA is 31 July 2024